Peptide receptor radionuclide therapy combinations for neuroendocrine tumours in ongoing clinical trials: status 2023.

In the Phase 3 NETTER-1 study 2 , with a median follow-up of >6.3 years, the pre-specified final analysis of OS in the intention-to-treat population did not reach statistical significance (HR, 0.84 [95% CI: 0.60, 1.17]; p = 0.30, two-sided) which was potentially impacted by a high rate of cross-over (36%) of patients in the control arm to PRRT.

also in 111,027 other papers